Lexicon Pharmaceuticals Inc
Statements
Cash Flow
Lexicon Pharmaceuticals Inc (LXRX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -24 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -35 | -49 | -85 | -32 | -34 | -34 | -47 | -53 | -22 | -27 | -26 | -27 | 191 | -24 | -22 | -46 | -40 | -34 | -25 | -22 | -17 | -23 | -23 | -24 | -19 | -22 | -32 | -38 | -42 | -51 | -55 | -49 | -54 | -21 | -44 | 17 | -24 | -17 | -15 | -24 | -80 | |
| 0.5 | 0.5 | 0.6 | 0.9 | 0.9 | 0.9 | 0.9 | 0.9 | 0.9 | 0.9 | 0.9 | 0.9 | 0.9 | 0.9 | 0.9 | 0.9 | 0.8 | 0.3 | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | 0.2 | 0.2 | 0.1 | 0.1 | 0.2 | 0.6 | |
| 1.9 | 1.7 | 2.2 | 2.4 | 2.6 | 2.3 | 3.1 | 2.9 | 2.9 | 2.8 | 3.4 | 3.8 | 3.6 | 3.5 | 4.4 | 4.3 | 1.9 | 2.7 | 2.9 | 2.8 | 2.7 | 2.2 | 2.8 | 2.8 | 2.6 | 3.3 | 3.4 | 3.8 | 3.9 | 3.2 | 4.3 | 4.9 | 2.8 | 1.5 | 3.0 | 3.2 | 3.4 | 2.8 | 3.1 | 6.4 | 16 | |
| -0.2 | 1.7 | -4.3 | 2.4 | 2.6 | -1.8 | 3.1 | 2.9 | 2.9 | 2.8 | 3.4 | 3.8 | 26 | -25 | 4.4 | 4.3 | 1.9 | 2.0 | 2.9 | 2.8 | 2.7 | 2.3 | 2.8 | 2.8 | 2.6 | 3.3 | 3.4 | 3.8 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.4 | -19 | -47 | -0.6 | -6.9 | -4.7 | -9.0 | -22 | 1.2 | -15 | -8.5 | -8.9 | -63 | 22 | 39 | 16 | 6.6 | -30 | -7.1 | -6.7 | 3.1 | 0.4 | -2.9 | -2.9 | 1.0 | 5.2 | -3.5 | 2.6 | 7.9 | -4.3 | -11 | 4.3 | 9.7 | 12 | -19 | 11 | -14 | -4.5 | -16 | -1.9 | -37 | |
| 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.9 | 0.2 | 0.0 | 0.1 | 0.0 | 0.0 | 1.2 | 0.2 | 0.1 | 0.1 | 0.0 | 0.0 | 0.3 | 0.3 | 0.5 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| 34 | 56 | 42 | 57 | 87 | -136 | 7.1 | 47 | 56 | 59 | -7.7 | -7.5 | -31 | -109 | 43 | 78 | 216 | 44 | -18 | 14 | -0.4 | 6.1 | -4.4 | -14 | -77 | 24 | 12 | -75 | -39 | 52 | -110 | -12 | 53 | 54 | 41 | 15 | 52 | 4.8 | -70 | -87 | -100 | |
| 0.0 | 0.0 | 0.5 | 0.0 | 0.0 | 0.0 | 0.6 | 0.0 | 0.0 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 0.1 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 2.2 | 0.7 | -1.7 | 4.3 | 0.1 | 2.5 | -1.0 | 0.4 | 0.2 | 0.2 | -0.9 | 0.0 | 0.0 | 0.0 | -0.9 | -0.1 | -1.0 | 1.0 | -2.7 | -2.7 | -2.7 | 0.4 | -0.9 | 0.0 | 94 | -0.1 | -0.8 | 139 | -0.2 | 0.2 | -1.7 | 0.0 | 0.0 | 0.0 | -0.6 | – | – | 0.0 | – | – | – | |
| -0.5 | -0.5 | -0.5 | -0.6 | -0.6 | 145 | -0.6 | -0.6 | -0.5 | -0.3 | -0.3 | -0.3 | -0.3 | -0.3 | -0.3 | -0.3 | -210 | -5.8 | -12 | -12 | -12 | -12 | 24 | -0.2 | -0.2 | 25 | 50 | 50 | – | – | – | – | 0.0 | 0.0 | 0.0 | -45 | 0.0 | -3.0 | -5.0 | 0.7 | -7.3 | |
| 1.7 | 0.2 | -1.1 | 3.7 | -0.5 | 148 | -1.5 | -0.2 | -0.4 | -0.1 | -1.3 | -0.3 | -0.3 | -0.3 | -1.2 | -0.4 | -210 | 64 | 14 | 0.0 | 20 | -11 | 23 | 94 | 94 | 25 | -0.8 | 189 | -0.2 | 0.0 | 239 | 0.0 | -0.9 | -0.1 | -0.6 | -45 | 0.0 | -2.9 | 89 | 88 | 174 | |
| 0.4 | 7.8 | -44 | 28 | 53 | -22 | -41 | -5.4 | 34 | 31 | -35 | -35 | 159 | -134 | 19 | 31 | -35 | 74 | -29 | -7.8 | 2.2 | -28 | -4.5 | -38 | -2.6 | 28 | -20 | 76 | -81 | 1.3 | 74 | -61 | -1.1 | 32 | -3.8 | -13 | 28 | -15 | 3.8 | -22 | -5.7 | |
| -35 | -49 | -86 | -32 | -34 | -34 | -47 | -53 | -22 | -27 | -26 | -27 | 191 | -24 | -22 | -46 | -40 | -34 | -25 | -23 | -17 | -23 | -23 | -24 | -19 | -23 | -32 | -38 | -42 | -51 | -55 | -49 | -54 | -22 | -44 | 17 | -24 | -17 | -15 | -24 | -80 |
LTM = last twelve months (sum of the four most recent quarters).
Showing the most recent 40 periods — older statements are on file for this stock.
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.